OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

Summary by AI BETAClose X

OKYO Pharma announced that its Chief Scientific Officer, Raj Patil, PhD, purchased 3,363 ordinary shares on NASDAQ at $1.49 per share, increasing his total holding to 20,030 shares. This insider buying activity occurs as the company prepares to initiate a global Phase 3 pivotal clinical trial in the second half of the year, which will enroll approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain.

Disclaimer*

UK 100

Latest directors dealings